Skip to main content
. 2016 Aug 11;7(40):65185–65195. doi: 10.18632/oncotarget.11218

Figure 4. Changes of driver genes in different lesions with EGFR-TKI.

Figure 4

A. Before EGFR-TKI treatment, the pathology of lung lesion was adenocarcinoma, EGFR mutation detected by sequencing was exon 19 deletion, and ALK was positive B. After EGFR-TKI treatment, the pathology of the right main bronchus was mixed small-cell lung cancer with adenocarcinoma; EGFR mutation detected by ARMS was exon 19 deletion. ALK rearrangement was negative C. the pathology of the lesion in the left upper lung lobe was adenocarcinoma, EGFR mutation was exon 19 deletion and exon 20 T790M mutation. AC, adenocarcinoma. ALK, anaplastic lymphoma kinase. DEL, deletion.EGFR, epidermal growth factor receptor.SCLC, small-cell lung cancer.